Reply to letter to the editor: The effects of bariatric surgery on fracture risk: Is there a significant higher risk?

2018 ◽  
Vol 20 (4) ◽  
pp. 631-632
Author(s):  
Qi Zhang ◽  
Jing Li ◽  
Qin Wang
Keyword(s):  
Bariatric Surgery ◽  
Fracture Risk ◽  
Letter To The Editor

Reply Letter to the Editor “The Outcome of Bariatric Surgery in Patients Aged 75 years and Older”

2018 ◽  
Vol 28 (10) ◽  
pp. 3310-3311
Author(s):  
Zubaidah Nor Hanipah ◽  
Philip R. Schauer
Keyword(s):  
Bariatric Surgery ◽  
Letter To The Editor

Response to “Letter to the Editor” in Regard to the Article: “Improvement of Coronary Calcium Scores After Bariatric Surgery in People with Severe Obesity”

2022 ◽  
Author(s):  
Ahmed Abdallah Salman ◽  
Mohamed Matter ◽  
Nabil Ibrahim Fayad ◽  
Mohamed S. Abd Elaziz Shehata ◽  
Mohamed Abd Al-Fattah ◽  
...  
Keyword(s):  
Bariatric Surgery ◽  
Severe Obesity ◽  
Coronary Calcium ◽  
Letter To The Editor

scholarly journals Effects of obesity treatments on bone mineral density, bone turnover and fracture risk in adults with overweight or obesity

2016 ◽  
Vol 28 (3) ◽  
Author(s):  
Claudia Harper ◽  
Andrea L. Pattinson ◽  
Hamish A. Fernando ◽  
Jessica Zibellini ◽  
Radhika V. Seimon ◽  
...  
Keyword(s):  
Bone Mineral Density ◽  
Bariatric Surgery ◽  
Weight Loss ◽  
Bone Turnover ◽  
Fracture Risk ◽  
Bone Mineral ◽  
Dietary Restriction ◽  
Mineral Density ◽  
Pre Treatment ◽  
Obesity Treatments

AbstractBackground:New evidence suggests that obesity is deleterious for bone health, and obesity treatments could potentially exacerbate this.Materials and methods:This narrative review, largely based on recent systematic reviews and meta-analyses, synthesizes the effects on bone of bariatric surgery, weight loss pharmaceuticals and dietary restriction.Results and conclusions:All three obesity treatments result in statistically significant reductions in hip bone mineral density (BMD) and increases in bone turnover relative to pre-treatment values, with the reductions in hip BMD being strongest for bariatric surgery, notably Roux-en Y gastric bypass (RYGB, 8%–11% of pre-surgical values) and weakest for dietary restriction (1%–1.5% of pre-treatment values). Weight loss pharmaceuticals (orlistat or the glucagon-like peptide-1 receptor agonist, liraglutide) induced no greater changes from pre-treatment values than control, despite greater weight loss. There is suggestive evidence that liraglutide may increase bone mineral content (BMC) – but not BMD – and reduce fracture risk, but more research is required to clarify this. All three obesity treatments have variable effects on spine BMD, probably due to greater measurement error at this site in obesity, suggesting that future research in this field could focus on hip rather than spine BMD. Various mechanisms have been proposed for BMD loss with obesity treatments, notably reduced nutritional intake/absorption and insufficient exercise, and these are potential avenues for protection against bone loss. However, a pressing outstanding question is whether this BMD reduction contributes to increased fracture risk, as has been observed after RYGB, and whether any such increase in fracture risk outweighs the risks of staying obese (unlikely).

Sign in / Sign up

Export Citation Format

Share Document